A randomized, placebo-controlled trial, ASSessing the effect of Anti-IL-6 treatment in Myocardial Infarction (ASSAIL-MI), demonstrated that IL-6R inhibition with tocilizumab administered during PCI in patients with STEMI reduced the inflammatory response and myocardial damage [4]. Here, IL6 is linked to myocardial infarction.